Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$11.03 USD
+0.15 (1.38%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $11.03 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ROIV 11.03 +0.15(1.38%)
Will ROIV be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ROIV
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Lags Revenue Estimates
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
Other News for ROIV
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
Cantor Fitzgerald biopharma analyst holds analyst/industry conference call
Tourlite Capital Q1 2024 Investor Letter
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis